Results 11 to 20 of about 4,821 (183)

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity [PDF]

Journal of Obesity & Metabolic Syndrome
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chae Won Chung, Jaetaek Kim
doaj   +2 more sources

Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases [PDF]

Basic & Clinical Pharmacology & Toxicology, 2020
AbstractThe prevalence of obesity and associated comorbidities such as type 2 diabetes and cardiovascular disease is increasing globally. Body‐weight loss reduces the risk of morbidity and mortality in obese individuals, and thus, pharmacotherapies that induce weight loss can be of great value in improving the health and well‐being of people living ...
Zakariassen, Hannah Louise, John, Linu Mary, Lutz, Thomas A   +2 more
openaire   +6 more sources

Amylin receptor subunit interactions are modulated by agonists and determine signaling [PDF]

Science Signaling
AbstractThree amylin receptors (AMYRs) mediate the metabolic actions of the peptide hormone amylin and are drug targets for diabetes and obesity. AMY1R, AMY2R, and AMY3R are heterodimers consisting of the G protein-coupled calcitonin receptor (CTR) paired with a RAMP1, -2, or -3 accessory subunit, respectively, which increases amylin potency. Little is
Sandra E. Gostynska, Jordan A. Karim, Bailee E. Ford, Peyton H. Gordon, Katie M. Babin, Asuka Inoue, Nevin A. Lambert, Augen A. Pioszak   +7 more
openaire   +4 more sources

Incretin-Related Pathology and Serum Exosome Detection in Experimental Alcohol-Related Brain Damage [PDF]

Biomolecules
Alcohol’s chronic neurotoxic and degenerative effects mediate alcohol-related brain damage (ARBD), which is marked by neurobehavioral, cognitive, and motor deficits.
Suzanne M. de la Monte, Ming Tong, Yiwen Yang   +2 more
doaj   +2 more sources

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3Research in context [PDF]

EBioMedicine
Summary: Background: Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 ...
Alexandra Oliveira Carvas, Andrea Leuthardt, Patricia Kulka, Greta Lommi, Shad Hassan, Bernd Coester, Sofia Lundh, Tune Pers, Anna Secher, Kirsten Raun, Thomas A. Lutz, Christelle Le Foll   +11 more
doaj   +2 more sources

Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models

Biomedicine & Pharmacotherapy, 2022
Cagrilintide is a novel long-acting amylin receptor agonist, which has shown a potent induction of weight loss. Interestingly, cagrilintide is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) derived from an amylin backbone. Another class of long-acting DACRAs exists, namely the KBPs.
A T, Larsen, K E, Mohamed, N, Sonne, E, Bredtoft, F, Andersen, M A, Karsdal, K, Henriksen   +6 more
openaire   +4 more sources

Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines [PDF]

Medicina
Obesity is a chronic, relapsing disease with multifactorial origins and significant global health implications. Historically, bariatric surgery has been the most effective intervention for achieving sustained weight loss and metabolic improvement ...
Safi G. Alqatari, Abrar J. Alwaheed, Manal A. Hasan, Reem J. Al Argan, Marj M. Alabdullah, Mohammed D. Al Shubbar   +5 more
doaj   +2 more sources

Pharmacotherapy for Obesity: Recent Updates [PDF]

Clinical Pharmacology: Advances and Applications
Thomas Ward Fredrick, Michael Camilleri, Andres Acosta Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USACorrespondence: Michael Camilleri, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905 ...
Fredrick TW, Camilleri M, Acosta A
doaj   +2 more sources

Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies [PDF]

Molecular Neurodegeneration
The potential neuroprotective effects of antidiabetic treatments have been largely assessed in Alzheimer’s disease (AD) and AD-like dementia models, with or without metabolic disorders.
Miriam Corraliza-Gomez, Maria Vargas-Soria, Monica Garcia-Alloza   +2 more
doaj   +2 more sources

Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin

Frontiers in Psychiatry, 2023
Alcohol use disorder (AUD) contributes substantially to global morbidity and mortality. Given the heterogenicity of this brain disease, available pharmacological treatments only display efficacy in sub-set of individuals.
Maximilian Tufvesson-Alm, Olesya T. Shevchouk, Elisabet Jerlhag   +2 more
doaj   +1 more source